

AstraZeneca 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/531,844	Applicant: Jahic <i>et al</i>
371 Filing Date: April 18, 2005	Attorney Docket No.: 100874-1P US
Examiner: Christopher Bull	Group Art Unit: 1655
Customer No.: 44992	Confirmation No.: 8121
Title: SCREENING ASSAY TO IDENTIFY INHIBITORS OF THE MURD ENZYME USING AN ACTIVATOR-INDEPENDENT MURD ENZYME	

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SEQUENCE LISTING STATEMENT

Sir:

The following statement is in support of a computer readable form of submission under 37 C.F.R. § 1.821(f). In compliance with 37 C.F.R. §1.821(f), the information recorded in the computer readable form is identical to the paper copy of the substitute Sequence Listing. In accordance with 37 C.F.R. §1.821(g), the Sequence Listing submitted herewith does not add new matter to the application.

Respectfully submitted,



Name: Christine McCormack
Dated: October 2, 2006
Reg. No.: L0065
Phone No.: 781 839 4693

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451